Terms: = Lymphoma AND ACVR1, SKR1, 90, ENSG00000115170, Q04771, ACVRLK2, FOP, ALK2, ACTRI AND Clinical Outcome
119 results:
1. Real-world data from yttrium-90 ibritumomab tiuxetan treatment of relapsed or refractory indolent B-cell non-Hodgkin's lymphoma: J3Zi Study.
Choi I; Okada M; Ito T
Ann Hematol; 2023 May; 102(5):1149-1158. PubMed ID: 36995403
[TBL] [Abstract] [Full Text] [Related]
2. [The impact of donor-to-recipient gender compatibility on outcomes of haploid hematopoietic stem cell transplantation in patients with hematological malignancies].
Hu SS; Wu YB; Zhu PP; Shi JM; Yu J; Zhao YM; Lai XY; Liu LZ; Fu HR; Huang H; Luo Y
Zhonghua Xue Ye Xue Za Zhi; 2022 Dec; 43(12):992-1002. PubMed ID: 36709104
[No Abstract] [Full Text] [Related]
3. Deep learning-based classifier of diffuse large B-cell lymphoma cell-of-origin with clinical outcome.
Viswanathan A; Kundal K; Sengupta A; Kumar A; Kumar KV; Holmes AB; Kumar R
Brief Funct Genomics; 2023 Jan; 22(1):42-48. PubMed ID: 36412115
[TBL] [Abstract] [Full Text] [Related]
4. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
5. Sensitive Measurement of Minimal Residual Disease in Blood by HAT-PCR.
Latham S; Hughes E; Budgen B; Ross D; Greenwood M; Bradstock K; Dalla-Pozza L; Huang L; Law T; Doculara L; Venn N; Ullah S; Sutton R; Morley AA
J Mol Diagn; 2022 Jun; 24(6):632-641. PubMed ID: 35430373
[TBL] [Abstract] [Full Text] [Related]
6. Childhood aggressive B-cell non-Hodgkin lymphoma in low-middle-income countries.
Moleti ML; Testi AM; Foà R
Br J Haematol; 2022 Feb; 196(4):849-863. PubMed ID: 34866182
[TBL] [Abstract] [Full Text] [Related]
7. The pathological features of leukemic cells infiltrating the renal interstitium in chronic lymphocytic leukemia/small lymphocytic lymphoma from a large single Chinese center.
Wang H; Yu X; Zhang X; Wang S; Zhao M
Diagn Pathol; 2021 Jul; 16(1):59. PubMed ID: 34218814
[TBL] [Abstract] [Full Text] [Related]
8. clinical features and prognostic impact of TCF3-PBX1 in childhood acute lymphoblastic leukemia: A single-center retrospective study of 837 patients from China.
Jia M; Hu BF; Xu XJ; Zhang JY; Li SS; Tang YM
Curr Probl Cancer; 2021 Dec; 45(6):100758. PubMed ID: 34034913
[TBL] [Abstract] [Full Text] [Related]
9. Improved clinical outcome in a randomized phase II study of anti-PD-1 camrelizumab plus decitabine in relapsed/refractory Hodgkin lymphoma.
Liu Y; Wang C; Li X; Dong L; Yang Q; Chen M; Shi F; Brock M; Liu M; Mei Q; Liu J; Nie J; Han W
J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33820822
[TBL] [Abstract] [Full Text] [Related]
10. The factors influencing clinical outcomes after leukapheresis in acute leukaemia.
Lee H; Park S; Yoon JH; Cho BS; Kim HJ; Lee S; Kim DW; Chung NG; Cho B; Kim KB; Yoo J; Jekarl DW; Chae H; Lim J; Kim M; Oh EJ; Kim Y
Sci Rep; 2021 Mar; 11(1):6426. PubMed ID: 33742034
[TBL] [Abstract] [Full Text] [Related]
11. The circuitry of the tumor microenvironment in adult and pediatric Hodgkin lymphoma: cellular composition, cytokine profile, EBV, and exosomes.
Nagpal P; Descalzi-Montoya DB; Lodhi N
Cancer Rep (Hoboken); 2021 Apr; 4(2):e1311. PubMed ID: 33103852
[TBL] [Abstract] [Full Text] [Related]
12. Impact of treatment variability and clinicopathological characteristics on survival in patients with Epstein-Barr-Virus positive diffuse large B cell lymphoma.
Witte HM; Merz H; Biersack H; Bernard V; Riecke A; Gebauer J; Lehnert H; von Bubnoff N; Feller AC; Gebauer N
Br J Haematol; 2020 Apr; 189(2):257-268. PubMed ID: 31958882
[TBL] [Abstract] [Full Text] [Related]
13. A Ukrainian multicenter prospective study of the value of PET/ CT prognostic role in primary patients with Hodgkins lymphoma in a real-life cohort.
Novosad O; Skrypets T; Pastushenko I; Kadnikova T; Gorbach O; Kozlov V; Mykhalska L; Kosinova V; Kostiukova N; Karnabeda O; Stratienko V; Novikov M; Oliinichenko O; Kmetyuk I; Karpova O; Ashykhmin A; Lukjanec O; Kriachok I
Klin Onkol; 2020; 33(6):450-457. PubMed ID: 33685195
[TBL] [Abstract] [Full Text] [Related]
14. Aggressive B-cell lymphoma: chasing the target.
Walewski J
J Investig Med; 2020 Feb; 68(2):331-334. PubMed ID: 31672721
[TBL] [Abstract] [Full Text] [Related]
15. Very early lineage-specific chimerism after reduced intensity stem cell transplantation is highly predictive of clinical outcome for patients with myeloid disease.
Kinsella FAM; Inman CF; Gudger A; Chan YT; Murray DJ; Zuo J; McIlroy G; Nagra S; Nunnick J; Holder K; Wall K; Griffiths M; Craddock C; Nikolousis E; Moss P; Malladi R
Leuk Res; 2019 Aug; 83():106173. PubMed ID: 31276965
[TBL] [Abstract] [Full Text] [Related]
16. Heterogeneity among diffuse large B-cell lymphoma: new entities in WHO classification, a first step in personalized therapy.
Rotaru I; Tănase AD; Nacea JG; Pătraşcu Ş; Olteanu OA; Pătraşcu AM
Rom J Morphol Embryol; 2019; 60(1):41-48. PubMed ID: 31263826
[TBL] [Abstract] [Full Text] [Related]
17. Predictive value of soluble interlukin-2 receptor level at diagnosis on the outcome for patients with classical Hodgkin lymphoma treated with ABVD with or without radiotherapy.
Umino K; Fujiwara SI; Ikeda T; Kawaguchi SI; Toda Y; Ito S; Ochi SI; Nagayama T; Mashima K; Minakata D; Nakano H; Yamasaki R; Morita K; Kawasaki Y; Yamamoto C; Ashizawa M; Hatano K; Sato K; Oh I; Ohmine K; Muroi K; Kanda Y
Ann Hematol; 2019 Sep; 98(9):2121-2129. PubMed ID: 31240469
[TBL] [Abstract] [Full Text] [Related]
18. [Long-term clinical outcome of children and adolescents with Burkitt's lymphoma treated with rituximab combined with modified NHL-BFM-90 regimen].
Li YX; Yin QS; Ai H; Mi RH; Zhang LN; Li YF; Wei XD; Song YP
Zhonghua Yi Xue Za Zhi; 2019 Feb; 99(8):605-610. PubMed ID: 30818930
[No Abstract] [Full Text] [Related]
19.
Bond J; Touzart A; Leprêtre S; Graux C; Bargetzi M; Lhermitte L; Hypolite G; Leguay T; Hicheri Y; Guillerm G; Bilger K; Lhéritier V; Hunault M; Huguet F; Chalandon Y; Ifrah N; Macintyre E; Dombret H; Asnafi V; Boissel N
Haematologica; 2019 Aug; 104(8):1617-1625. PubMed ID: 30655366
[TBL] [Abstract] [Full Text] [Related]
20. Genomic alterations important for the prognosis in patients with follicular lymphoma treated in SWOG study S0016.
Qu X; Li H; Braziel RM; Passerini V; Rimsza LM; Hsi ED; Leonard JP; Smith SM; Kridel R; Press O; Weigert O; LeBlanc M; Friedberg JW; Fang M
Blood; 2019 Jan; 133(1):81-93. PubMed ID: 30446494
[TBL] [Abstract] [Full Text] [Related]
[Next]
